Ken Tajima 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（17 件）

• [2025] Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra‐Terminal Domain Inhibitors
  DOI: https://doi.org/10.1111/cas.70032
• [2024] Second malignancy in advanced or recurrent non‐small cell lung cancer after the advent of molecular targeted drugs and immunotherapy
  DOI: https://doi.org/10.1111/1759-7714.15457
• [2024] <scp>Anti‐Müllerian</scp> hormone type <scp>II</scp> receptor protein expression in non‐small cell lung cancer and the effect of <scp>AMH</scp>/<scp>AMHR2</scp> signaling on cancer cell proliferation
  DOI: https://doi.org/10.1111/1759-7714.15309
• [2024] Clinical potential of SKP2 as diagnostic marker and therapeutic target in small cell lung cancer
  DOI: https://doi.org/10.1016/j.resinv.2024.07.014
• [2024] Multimodal fully automated predictive model for therapeutic efficacy of first-line cancer immunotherapy based on clinical information and imaging modalities including brain MRI and chest CT images in advanced non-small cell lung cancer.
  DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1555
• [2024] Trophoblast Cell Surface Antigen 2 Expression in Thymic Carcinoma: Brief Report
  DOI: https://doi.org/10.1016/j.jtocrr.2024.100693
• [2023] <scp>CALML5</scp> is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type <scp>B3</scp> thymoma
  DOI: https://doi.org/10.1111/1759-7714.14853
• [2023] Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
  DOI: https://doi.org/10.3390/cancers15041170
• [2023] Comparison of <scp>ASCL1</scp>, <scp>NEUROD1</scp>, and <scp>POU2F3</scp> expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma
  DOI: https://doi.org/10.1111/his.14872
• [2022] Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
  DOI: https://doi.org/10.1186/s12885-022-09421-7

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。